Oct 26 (Reuters) - Indian drugmaker Mankind Pharma reported an over 39% jump in second-quarter profit on Monday, helped by ...
Going ahead, improving domestic volumes, rising chronic contribution and sustained export momentum are expected to support ...
Mankind Pharma shares surged 4.5 percent after Q2 FY27 net profit jumped 39.2 percent and revenue rose 17.3 percent. EBITDA margin expanded by 210 basis points to 27 percent.
For the first half of FY27, revenue from operations rose 15.1% YoY to ₹8,368 crore. EBITDA increased 26% to ₹2,235 crore, ...
Mankind Pharma’s operating margin widened to 27% from 24.9% a year earlier. Its board also approved plans to merge two wholly ...
The drugmaker's revenue rose 17.3 per cent to ₹4,338 crore in Q2 FY27, supported by strong demand for chronic therapies and ...
Mankind Pharma's employee benefits expenses surged by 15% to Rs 949 crore in Q2 FY27, reflecting the company's expansion and ...
Mankind Pharma, AIOS and EBAI organised Vision Continuum 2026 to raise awareness about corneal health, eye donation, and ...
Mankind Pharma Ltd (NSE:MANKIND) delivered strong Q2 FY27 results with revenue of INR4,338 crores, PAT growth of 37.7%, and international business surging 33% YoY, even as consumer healthcare lagged.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results